Remaining questions in ductal carcinoma in situ
6 Views
administrator
06/19/23
Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, comments on additional lines of research within the field of ductal carcinoma in situ (DCIS). Previous studies have identified a number of patients with DCIS who are HER2 positive and respond to trastuzumab. Further research is subsequently required to ****ess whether patients who have a residual risk and are HER2 positive will benefit from receiving trastuzumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
-
Category
Show more
Facebook Comments
No comments found